Antimicrobial resistance, one of the world’s biggest killers, has reached an alarming tipping point.

Changing the way antibiotics are developed and accessed.

A public-health driven model to tackle AMR.

Our latest news and resources.

Protecting people from the rise and spread of drug-resistant infections.

Supporting efforts to ensure the right antibiotics are developed and reach the people who need them.

Our partners.

Weaving a global ecosystem against AMR.

Antibiotic resistance is a global health challenge that demands a global response. GARDP works through equal partnerships, working closely with governments in both the Global North and Global South, and across the public and private sectors. It brings together scientists, clinicians, industry, manufacturers, donors, and civil society to carry out and coordinate efforts in antibiotic development and access.

Through these relationships, we build a coordinated ecosystem that pools scientific expertise, funding and geographic reach to accelerate impact. While our team brings in valuable contributions to partners, we in turn benefit from their wealth of knowledge, local expertise and experience. 

Today, our growing network includes more than 100 partners across 27 countries, working collectively towards a world where everyone has access to next-generation antibiotics to treat drug-resistant infections. 

Our partners from across the globe

Filter by

*updated december 2025

GARDP Partners

  • Discovery & Exploratory Research
  • Drug Development
  • Access to Antibiotics
  • Scientific Affairs & REVIVE

Trial or study sites

  • Discovery & Exploratory Research
  • Drug Development
  • Access to Antibiotics
our R&D and access partners

Insights from our partners

Thumbnail MMV GARDP DNDi PR2026 (1)

DNDi, GARDP, and MMV join forces to accelerate drug development for patients in greatest need

Read more
HERA 3 funding

The European Commission invests in CARB-X and GARDP to ramp up global response to antimicrobial resistance

Read more
High throughput screening

Antabio and GARDP join forces to identify potential next-generation antibiotics

Read more
View more

GARDP’s global network.

Our global network is designed to unlock the expertise of different countries and help address the burden of AMR where it is most needed. The network of offices in strategic locations strengthens our geographic footprint and helps optimize resources.

Our network

“We needed external collaborations and partners who had experience in bringing products to LMICs as well as an understanding of the unique challenges in enabling patient access to Reserve antibiotics. We found the right partners in GARDP and CHAI and now Orchid. Through these collaborations, we are working to provide expanded, accelerated, and sustainable access to cefiderocol.”

Monika Schneider, Senior Director Global Infectious Disease Policy, Shionogi Inc.

“We are at a pivotal moment in the global fight against antimicrobial resistance, and international collaboration is more important than ever. The UK is proud to continue this partnership with GARDP, driving life-saving innovations such as the first new antibiotic for drug-resistant gonorrhoea in over 30 years. We remain committed to working with GARDP to ensure that these vital treatments reach those who need them most around the world.”

Dame Sally Davies, UK Special Envoy for AMR

“AMR is a growing global challenge and only through joint public research funding, resilient partnerships and sustained investment can we protect public health in Europe and worldwide. The German Federal Ministry of Research, Technology and Space therefore supports international initiatives such as CARB-X and GARDP.”

Matthias Hauer, Parliamentary Secretary of State, German Federal Ministry of Research, Technology and Space